Related Experiment Video
Updated: May 21, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
[HTLV-1-Associated Myelopathy]
Makoto Nakashima1, Yoshihisa Yamano
1Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine.
Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy (HAM) causes spinal cord inflammation and damage. Cerebrospinal fluid biomarkers help assess disease activity for better treatment outcomes in HAM patients.
Area of Science:
- Neuroimmunology
- Viral Neurology
- Spinal Cord Disorders
Background:
- Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy (HAM) is a chronic neuroinflammatory disease.
- HTLV-1 infection leads to T-cell infiltration in the spinal cord, causing neurological damage, primarily in the mid-to-lower thoracic regions.
- Effective management of HAM necessitates precise evaluation of disease activity and prompt therapeutic intervention.
Purpose of the Study:
- To investigate the clinical utility of cerebrospinal fluid (CSF) biomarkers for stratifying disease activity in HAM.
- To establish a foundation for timely and targeted therapeutic strategies in HAM patients.
Main Methods:
- Analysis of CSF biomarkers in a cohort of HAM patients.
- Correlation of biomarker levels with clinical disease severity and progression.
- Evaluation of biomarker performance in distinguishing different levels of disease activity.
Main Results:
- Specific CSF biomarkers were identified as significant indicators of active neuroinflammation in HAM.
- Biomarker profiles effectively stratified patients into distinct disease activity groups.
- These findings suggest CSF analysis can guide clinical decision-making.
Conclusions:
- Cerebrospinal fluid biomarker stratification offers a clinically useful tool for assessing disease activity in HTLV-1-associated myelopathy.
- This approach supports personalized treatment strategies and has the potential to improve long-term outcomes for HAM patients.
Related Concept Videos
Huntington Disease l: Introduction
Encephalitis ll: Pathophysiology
Cytomegalovirus Disease
Secondary Spinal Cord Injury llI: Pathophysiology
Multiple Sclerosis l: Introduction
Viral Meningitis

